Therma Bright expands Venowave sales with Gen-X Med

Executive Summary

• Therma Bright Inc. has entered into a strategic partnership with Gen-X Med, a specialized medical product distributor, to expand the sales and distribution of its Venowave VW5 device.
• The partnership follows an initial successful pilot involving the sale of 200 Venowave VW5 units to patients undergoing specialized knee surgeries, demonstrating early market traction.
• The Venowave VW5 is a Medicare-approved, reimbursable mobile mechanical compression system (HCPCS code E0683) designed to improve circulation and lymphatic function, with clinical data showing significant improvements in venous blood flow.

Key Details

• Partnership Structure: Strategic distribution agreement between Therma Bright Inc. and Gen-X Med (Arlington, Texas-based distributor).
• Product Focus: Venowave VW5, a compact, battery-operated peristaltic pump for treating circulatory disorders.
• Initial Traction: The relationship was established following the initial sale of 200 Venowave VW5 units targeted at patients who had undergone specialized knee surgeries.
• Market Context: The partnership targets the high-value segment of specialized knee surgeries within the U.S. healthcare market.
• Device Specifications:
  • FDA-designated durable medical equipment (DME).
  • Medicare-approved and reimbursable under HCPCS code E0683.
  • Generates wave-like motion to improve blood circulation and lymphatic function.
• Clinical Performance Data:
  • Enhances venous blood flow by 64% after two minutes of use.
  • Enhances venous blood flow by 88% after 50 minutes of use.
• Market Size: Global compression therapy market valued at $4.18 billion in 2024, projected to reach $6.72 billion by 2033 (CAGR of 7.30% from 2025-2033).

Notable Quotes

• Beau Wood, President, Gen-X Med: "We are pleased to partner with Therma Bright in offering the Venowave VW5 to our doctor network. We've seen great patient success with the initial 200-unit purchase and anticipate placing additional orders as we ramp up awareness and adoption of this special vascular compression therapy solution."
• Rob Fia, CEO, Therma Bright: "This partnership with Gen-X Med is a strategic step in expanding Venowave's presence into a focused and high-value market segment. We believe the Venowave offers significant advantages for patients and the U.S. health care system by reducing postsurgical complications and costly readmissions, which aligns with our mission to provide innovative and effective medical solutions that improve patient outcomes and create value."